PFNX Pfenex Inc.

5.83
+0.01  (+0%)
Previous Close 5.82
Open 5.71
Price To Book 3
Market Cap 183570370
Shares 31,487,199
Volume 69,612
Short Ratio 1.91
Av. Daily Volume 198,012

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date October 7, 2019.
PF708 and Forteo
Osteoporosis
Phase 2 trial to be initiated 2019 subject to funding.
Px563L
Anthrax vaccine
Phase 1/2 data released August 2016. Noted November 9, 2017 that development has been paused until strategic partnerships are forged.
PF582
Biosimilar candidate to Lucentis for retinal diseases
Phase 3 trial of partnered product met primary endpoint - March 6, 2019.
CRM197
Pneumococcal conjugate vaccine

Latest News

  1. Pfenex Announces Successful Expiration of 45 Day Waiting Period Under Hatch-Waxman Act
  2. Pfenex to Participate at the William Blair Late-Stage Therapeutics Conference
  3. Pfenex to Present at the 18th Annual Needham Healthcare Conference
  4. Pfenex to Present at the 29th Annual Oppenheimer & Co. Healthcare Conference
  5. Pfenex Appoints Dr. Martin B. Brenner as Chief Scientific Officer
  6. Will Pfenex Continue to Surge Higher?
  7. Edited Transcript of PFNX earnings conference call or presentation 11-Mar-19 8:30pm GMT
  8. Pfenex (PFNX) Reports Q4 Loss, Misses Revenue Estimates
  9. Pfenex Reports Fourth Quarter and Full Year 2018 Results and Provides Business Update
  10. Are Insiders Buying Pfenex Inc. (NYSEMKT:PFNX) Stock?
  11. Pfenex Licensee Successfully Completes a Phase 3 Study and Enters Registration for Pneumosil®
  12. Pfenex Announces Appointment of New Board Member, Magda Marquet, Ph.D.
  13. Pfenex and Alvogen Expand Development and Commercialization Collaboration for PF708, a Therapeutic Equivalent Candidate to Forteo®/Forsteo®, to the EU, MENA, and ROW
  14. Pfenex to Participate at Two Investor Conferences in March
  15. Pfenex to Host Conference Call and Webcast Reporting Fourth Quarter Financial Results on Monday, March 11th
  16. Pfenex Announces FDA Acceptance of NDA for PF708
  17. Pfenex Submits New Drug Application to U.S. FDA Seeking Approval of PF708 for the Treatment of Osteoporosis
  18. Market Trends Toward New Normal in Suburban Propane Partners, Sanchez Midstream Partners LP, Imperial Oil, Pfenex, National Commerce, and Yuma Energy — Emerging Consolidated Expectations, Analyst Ratings
  19. Edited Transcript of PFNX earnings conference call or presentation 7-Nov-18 9:30pm GMT
  20. Pfenex Reports Third Quarter Results and Provides Business Update